Form
SCHEDULE 13G/A
Passive or exempt beneficial ownership filing.
Adjuvant Global Health Technology Fund, L.P. - 31 Dec 2024 SCHEDULE 13G/A Report for AN2 Therapeutics, Inc. Common Stock, $0.00001 par value per share (ANTX)
- Filing manager
- Adjuvant Global Health Technology Fund, L.P.
- Reporting owner
- Adjuvant Capital GP, L.P.
- Beneficially owned shares
- 2,373,500 shares
- Large-stake signal
-
Ownership
7.9%Beneficial ownership of this reported class.
Shares
2,373,500 sharesShares beneficially owned as disclosed.
Event date
31 Dec 2024Date tied to the ownership event or amendment.
Accepted by SEC
28 Feb 2025EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 7.9%
- Symbol
- ANTX
- Shares outstanding
- 30,044,304 shares
- SEC form
- SCHEDULE 13G/A
- Accepted by SEC
- 28 Feb 2025, 19:57:57 UTC
- Event date
- 31 Dec 2024
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
4 source fields
Key filing fact
Adjuvant Global Health Technology Fund, L.P. disclosed 7.9% ownership in AN2 Therapeutics, Inc. Common Stock, $0.00001 par value per share (ANTX) on 31 Dec 2024.
Key facts
- Adjuvant Global Health Technology Fund, L.P. filed SCHEDULE 13G/A for AN2 Therapeutics, Inc. Common Stock, $0.00001 par value per share (ANTX).
- Disclosed ownership: 7.9%.
- Date of event: 31 Dec 2024.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 28 Feb 2025, 19:57.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (4)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Adjuvant Global Health Technology Fund, L.P. | 6.7% | 1,995,958 | 0 | 1,995,958 | /s/ Kabeer Aziz | Vice President and Secretary of Adjuvant Capital Management, L.L.C., the sole general partner of Adjuvant Capital GP, L.P. | |
| Adjuvant Global Health Technology Fund DE, L.P. | 1.3% | 377,542 | 0 | 377,542 | /s/ Kabeer Aziz | Vice President and Secretary of Adjuvant Capital Management, L.L.C., the sole general partner of Adjuvant Capital GP, L.P. | |
| Adjuvant Capital GP, L.P. | 7.9% | 2,373,500 | 0 | 2,373,500 | /s/ Kabeer Aziz | Vice President and Secretary of Adjuvant Capital Management, L.L.C., the sole general partner of Adjuvant Capital GP, L.P. | |
| Adjuvant Capital Management, L.L.C. | 7.9% | 2,373,500 | 0 | 2,373,500 | /s/ Kabeer Aziz | Vice President and Secretary |
CIK / CUSIP context first